A group of legal, ethics and genomics experts have attacked FDA's plans to regulate genomic tests as part of the agency's proposed laboratory developed tests (LDT) paradigm. They argue the agency lacks the statutory authority and resources to regulate the tests, and could stifle innovation.
The scholars, Barbara Evans, Wylie Burke, and Gail Jarvik, from the Universities of Houston and Washington, wrote in a May 27 article
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?